Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: A randomised controlled clinical trial

Journal of Psychopharmacology

Volumn 23, Issue 3, 2009, Pages 305-314

  Zink, M ^a   Kuwilsky, A ^a   Krumm, B ^a   Dressing, H ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Clozapine; Combination; Risperidone; Schizophrenia; Ziprasidone

Indexed keywords

BENZODIAZEPINE; CLONAZEPAM; CLOZAPINE; DOXEPIN; REBOXETINE; RISPERIDONE; VALPROIC ACID; ZIPRASIDONE;

ADD ON THERAPY; ADULT; AGITATION; AKATHISIA; ARTICLE; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EMOTIONAL DISORDER; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HAMILTON SCALE; HUMAN; MALE; NEGATIVE SYNDROME; PATIENT COMPLIANCE; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITIVE SYNDROME; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; SCHIZOAFFECTIVE PSYCHOSIS; SIDE EFFECT; SOCIAL PSYCHOLOGY; TREATMENT RESPONSE;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LONG QT SYNDROME; MALE; MIDDLE AGED; PIPERAZINES; PROLACTIN; PSYCHIATRIC STATUS RATING SCALES; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEVERITY OF ILLNESS INDEX; THIAZOLES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 65349177685     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881108089593     Document Type: Article

References (50)

1. Addington DE, Pantelis C, Dineen M, Benattia I, Romano SJ,. (2004) Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial. J Clin Psychiatry 65: 1624 - 1633.
2. Akdede B, Anil Yagcioglu AE, Alptekin K, Turgut TI, Tümü klü M, Yazici MK, (2007) A double-blind study of combination of clozapine with risperidone in patients with schizophrenia: effects on cognition. J Clin Psychiatry 67: 1912 - 1919.
3. Anil Yagcioglu AE, Kivircik Akdede BB, Turgut TI, Tumuklu M, Yazici MK, Alptekin K, (2005) A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. J Clin Psychiatry 66: 63 - 72.
4. Caley CF, Cooper CK,. (2002) Ziprasidone: the fifth atypical antipsychotic. Ann Pharmacother 36: 839 - 851. (Pubitemid 34517416)
5. Chan J, Sweeting M, (2007) Combination therapy with non-clozapine atypical antipsychotic medication: a review of current evidence. J Psychopharmacol. doi:10.1177/0269881106071334 [online-first]. (Pubitemid 47472722)
6. Daniel DG, Daniel DG, (2003) Tolerability of ziprasidone: an expanding perspective. J Clin Psychiatry 64 (Suppl. 19). 40 - 49.
7. Freudenreich O, Goff DC, (2002) Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations. Acta Psychiatr Scand 106: 323 - 330.
8. Freudenreich O, Henderson DC, Walsh JP, Culhane MA, Goff DC, (2007) Risperidone augmentation for schizophrenia partially responsive to clozapine: a double-blind, placebo-controlled trial. Schizophr Res 92: 90 - 94.
9. Gharabawi GM, Bossie CA, Mahmoud R, Canuso CM, Lasser RA, Turkoz I, (2006) Methodological issues in a comparative study of ziprasidone and risperidone. J Clin Psychiatry 67: 162 - 163.
10. Harrigan EP, Miceli JJ, Anziano R, Watsky E, Reeves KR, Cutler NR, (2004) A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol 24: 62 - 69. (Pubitemid 38134167)
11. Harvey PD, Meltzer H, Simpson GM, Potkin SG, Loebel A, Siu C, (2004) Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia. Schizophr Res 66: 101 - 113.
12. Hellewell JS, (1999) Treatment-resistant schizophrenia: reviewing the options and identifying the way forward. J Clin Psychiatry 60 (Suppl. 23). 14 - 19.
13. Henderson DC, Nguyen DD, Copeland PM, Hayden DL, Borba CP, Louie PM, (2005) Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study. J Clin Psychiatry 66: 1116 - 1121.
14. Heres S, Davis J, Maino K, Jetzinger E, Kissling W, Leucht S, (2006) Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. Am J Psychiatry 163: 185 - 194. (Pubitemid 44480836)
15. Honer WG, Thornton AE, Chen EY, Chan RC, Wong JO, Bergmann A, (2006) Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N Engl J Med 354: 472 - 482.
16. Josiassen RC, Joseph A, Kohegyi E, Stokes S, Dadvand M, Paing WW, (2005) Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry 162: 130 - 136.
17. Kane J, Honigfeld G, Singer J, Meltzer H, (1988) Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45: 789 - 796.
18. Karunakaran K, Tungaraza TE, Harborne G, (2006) Is clozapine-aripiprazole combination a useful regime in the management of treatment-resistant schizophrenia? J Psychopharmacol. doi:10.1177/0269881106068289 [online first].
19. Kaye NS, (2003) Ziprasidone augmentation of clozapine in 11 patients. J Clin Psychiatry 64: 215 - 216. (Pubitemid 36268327)
20. Lusskin SI, Cancro R, Chuang L, Jacobson J, (2004) Prolactin elevation with ziprasidone. Am J Psychiatry 161: 1925. (Pubitemid 39314693)
21. Mackin P, Young AH, (2005) QTc interval measurement and metabolic parameters in psychiatric patients taking typical or atypical antipsychotic drugs: a preliminary study. J Clin Psychiatry 66: 1386 - 1391. (Pubitemid 41779536)
22. McCue RE, Waheed R, Urcuyo L, (2003) Polypharmacy in patients with schizophrenia. J Clin Psychiatry 64: 984 - 989. (Pubitemid 37158242)
23. McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, (2006) Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 163: 600 - 610.
24. Meltzer HY, (1994) An overview of the mechanism of action of clozapine. J Clin Psychiatry 55 (Suppl. B). 47 - 52. (Pubitemid 24353016)
25. Miller DD; , (2000) Review and management of clozapine side effects. J Clin Psychiatry 61(Suppl. 8): 14-7; disc 18-19.
26. Munro J, Matthiasson P, Osborne S, Travis M, Purcell S, Cobb AM, (2004) Amisulpride augmentation of clozapine: an open non-randomized study in patients with schizophrenia partially responsive to clozapine. Acta Psychiatr Scand 110: 292 - 298.
27. Paton C, Whittington C, Barnes TR, (2007) Augmentation with a second antipsychotic in patients with schizophrenia who partially respond to clozapine: a meta-analysis. J Clin Psychopharmacol 27: 198 - 204. (Pubitemid 46594939)
28. Prakash C, Kamel A, Cui D, Whalen RD, Miceli JJ, Tweedie D, (2000) Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions. Br J Clin Pharmacol 49 (Suppl. 1). 35S - 42S. (Pubitemid 30151051)
29. Reinstein MJ, Sonnenberg JG, Mohan SC, Chasanov MA, Jones LE, (2003) Use of quetiapine to manage patients who experienced adverse effects with clozapine. Clin Drug Investig 23: 63 - 67.
30. Roden DM, (2004) Drug-induced prolongation of the QT interval. N Engl J Med 350: 1013 - 1022. (Pubitemid 38269278)
31. Schumacher JE, Makela EH, Griffin HR, (2003) Multiple antipsychotic medication prescribing patterns. Ann Pharmacother 37: 951 - 955.
32. Shiloh R, Zemishlany Z, Aizenberg D, Radwan M, Schwartz B, Dorfman-Etrog P, (1997) Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study. Br J Psychiatry 171: 569 - 573. (Pubitemid 27527329)
33. Spina E, de Leon J, (2007) Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol 100: 4 - 22.
34. Stahl SM, (2002) Antipsychotic polypharmacy: evidence based or eminence based? Acta Psychiatr Scand 106: 321 - 322.
35. Stahl SM, Grady MM, (2004) A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation. Curr Med Chem 11: 313 - 327.
36. Stroup TS, Alves WM, Hamer RM, Lieberman JA, Stroup TS, Alves WM, (2006) Clinical trials for antipsychotic drugs: design conventions, dilemmas and innovations. Nat Rev Drug Discov 5: 133 - 146.
37. Taylor D, Taylor D, (2003) Ziprasidone in the management of schizophrenia: the QT interval issue in context. CNS Drugs 17: 423 - 430.
38. Tovey E, Rampes H, Livingstone C, (2005) Clozapine-induced type-2 diabetes mellitus: possible mechanisms and implications for clinical practice. J Psychopharmacol 19: 207 - 210.
39. Wahlbeck K, Cheine MV, Essali A, (1999) Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database Syst Rev 4. doi:10.1002/14651858.CD000059.
40. Weiden PJ, Daniel DG, Simpson G, Romano SJ, (2003a) Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone. J Clin Psychopharmacol 23: 595 - 600.
41. Weiden PJ, Simpson GM, Potkin SG, O'Sullivan RL, (2003b) Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia. J Clin Psychiatry 64: 580 - 588.
42. Woods SW, (2003) Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 64: 663 - 667.
43. Xiang YQ, Zhang ZJ, Weng YZ, Zhai YM, Li WB, Cai ZJ, (2006) Serum concentrations of clozapine and norclozapine in the prediction of relapse of patients with schizophrenia. Schizophr Res 83: 201 - 210.
44. Ziegenbein M, Calliess IT, (2006) Clozapine and ziprasidone: a useful combination in patients with treatment-resistant schizophrenia. J Neuropsychiatry Clin Neurosci 18: 246 - 247.
45. Ziegenbein M, Kropp S, Kuenzel HE, (2005) Combination of clozapine and ziprasidone in treatment-resistant schizophrenia: an open clinical study. Clin Neuropharmacol 28: 220 - 224.
46. Zink M, (2005) Augmentation of olanzapine in treatment-resistant schizophrenia. J Psychiatry Neurosci 30: 409 - 415. (Pubitemid 41812487)
47. Zink M, Dressing H, (2005) Augmentation of clozapine with atypical antipsychotic substances. Curr Psychiatry Rev 1: 165 - 172.
48. Zink M, Knopf U, Henn FA, Thome J, (2004a) Combination of clozapine and amisulpride in treatment-resistent schizophrenia - case reports and review of the literature. Pharmacopsychiatry 37: 26 - 31.
49. Zink M, Mase E, Dressing H, (2004b) Combination of ziprasidone and clozapine in treatment-resistant schizophrenia. Hum Psychopharmacol 19: 271 - 273.
50. Zink M, Mase E, Dressing H, (2004c) Ziprasidone-augmentation of clozapine. Psychiatr Praxis 31: 259 - 261.